Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression

Journal of Laboratory and Clinical Medicine

Volumn 140, Issue 5, 2002, Pages 320-328

  Kataki, Agapi ^a   Scheid, Philippe ^a   Piet, Maud ^a   Marie, Beatrice ^a   Martinet, Nadine ^a   Martinet, Yves ^a   Vignaud, Jean Michel ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0036846118     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2002.128317     Document Type: Article

References (48)

1. Mulshine JL, Zhou J, Treston AM, Szabo E, Tockman MS, Cuttitta F. New approaches to the integrated management of early lung cancer. Hematol. Oncol. Clin North Am 1997;11: 235-2.
2. Sasco AJ. Lung cancer prevention: The point of view of a public health epidemiologist. In: Martinet Y, Hirsch FR, Martinet N, Vignaud JM, Mulshine JL, editors. Clinical and Biological Basis of Lung Cancer Prevention. Birkäuser, Basel: 1998:297-304.
3. Parker SL, Long T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996;65:5-27.
4. Mulshine JL, Treston AM, Tockman MS, Cuttitta F. Integrated approach to the management of early lung cancer. In: Brambilla C, Brambilla E, editors. Lung Tumors. Fundamental Biology and Clinical Management. Marcel Dekker, New York: 1998:335-45.
5. Weynants P. Lung cancer cell immunogenicity and immunotherapy. In: Brambilla C, Brambilla E, editors. Lung Tumors. Fundamental Biology and Clinical Management. Marcel Dekker, New York: 1998:709-28.
6. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Frederick M, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996;2:985-91.
7. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 89:21-39.
8. Weynants P, Marchandise FX, Sibille Y. Pulmonary perspective: Immunology in diagnosis and treatment of lung cancer. Eur Respir J 1997;10:1703-19.
9. World Health Organization. Histological Typing of Lung Tumors. World Health Organization, Geneva, 68 pp. 1981.
10. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S-33S.
11. Gratzner HG. Monoclonal antibody to 5-bromo and 5-iododeoxyuridine. A new reagent for detection of DNA replication. Science 1982;218:474-5.
12. Duprez A, Borrelly J, Grosdidier G, Hoffmann M, Boileau S. Cell kinetics of human tumors in vivo: Immuno-histochemical detection of 5-iododeoxyuridine incorporated into DNA of growing cells. C R Acad Sci Paris 1989;308:313-9.
13. Pech M, Durga Rao C, Robbins KC, Aaronson SA. Functional identification of regulatory elements within the promotor region of PDGF 2. Mol Cell Biol 1989;9:396-405.
14. Betsholtz C, Johansson A, Heldin CH, Westermark B, Lind P, Urdea MS, et al. cDNA sequence and chromosomal location of human platelet-derived growth factor A-chain and its expression in tumor cell lines. Nature 1986;320:695-9.
15. Melton DA, Krieg PA, Rebagliati MR, Maniatis T, Zinn K, Green MR. Efficient in vitro synthesis of biologically active RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res 1984;12:7035-56.
16. Cox KH, Deleon DV, Angerer LH, Angerer RC. Detection of mRNAs in sea urchin embryo in situ hybridization using asymetric RNA probes. Dev Biol 1984;101:485-502.
17. Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P. A polyadenylate binding protein localized to the granules of cytolyric lymphocytes induces DNA fragmentation in target cells. Cell 1991;67:629-39.
18. Vignaud JM, Marie B, Klein N, Plénat F, Pech M, Borrelly J, et al. The role of platelet-derived growth factor production by tumor-associated macrophages in tumor stroma formation in lung cancer. Cancer Res 1994;54:5455-63.
19. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 1993;91:566-76.
20. Van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 1992;67:166-74.
21. Kawakami A, Tian Q, Duan X, Streuli M, Schlossman SF, Anderson P. Identification and functional characterization of a TIA-1-related nucleolysin. Proc Natl Acad Sci U S A 1992;89: 8681-5.
22. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073-7.
23. Vignaud JM, Martinet Y, Martinet N. Role of growth factors in the stromal reaction in non-small cell lung carcinoma. In: Brambilla C, Brambilla E, editors. Lung Tumors. Fundamental Biology and Clinical Management. Marcel Dekker, New York: 1998;347-64.
24. Jassem J. Biological treatment of NSCLC. The need for conclusive studies. Chest 1996;109:119S-24S.
25. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349:13-5.
26. Endress H, Freudenberg N, Fitzke E, Grahmann PR, Hasse J, Dieter P. Infiltration of lung carcinomas with macrophages of the 27E10-positive phenotype. Lung Cancer 1997;18:35-46.
27. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990;11:97-101.
28. Walz A, Kunkel SL, Strieter RM. CXC chemokines: An overview. In: Koch AE, Strieter RM, editors. Chemokines in Disease. RG Landes, Austin: 1996:1-26.
29. Nabil K, Rihn B, Jaurand MC, Vignaud JM, Ripoche J, Martinet Y, et al. Identification of human complement factor H as a chemotactic protein for monocytes. Biochem J 1997;326:377-83.
30. Restifo NP, Wunderlich JR. Biology of cellular immune responses. In: De Vita VT, Jr, Hellman S, Rosenberg SA, editors. Biologic Therapy of Cancer. J.B. Lippincott, Philadelphia: 1995: 3-37.
31. Weynants P, Lethé B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 1994;56:6-829.
32. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer Cancer Res 1994;54:3387-90.
33. Melioli G, Ratto G, Guastella M, Meta M, Biassoni R, Semino C, et al. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: Functional and molecular characterisation for their use in adoptive immunotherapy. Eur J Cancer 1994;30:97-102.
34. Meta M, Ponte M, Guastella M, Semino C, Pietra G, Ratto GB, et al. Detection of oligoclonal T-lymphocytes in lymph nodes draining from advanced non-small cell lung cancer. Cancer Immunol. Immunother 1995;40:235-40.
35. Weynants P, Wauters P, Coulie PG, Van den Eynde B, Symann M, Boon T. Cytolytic response of human T cells against allogeneic small cell lung carcinoma treated with interferon gamma. Cancer Immunol Immunother 1988;27:228-32.
36. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
37. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376.
38. Roussel E, Gingras MC, Grimm EA, Roth JA. High expression of adhesion molecules/activation markers with little interleukin-2, interferon γ and tumor necrosis factor β gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. Cancer Immunol Immunother 1995;41:1-9.
39. Weissler JC, Nicod LP, Lipscomb MF, Toews GB. Natural killer cell function in human lung is compartmentalized. Am Rev Respir Dis 1987;135:941-9.
40. Pitchenik AE, Guffee J, Stein-Streilein J. Lung natural killer and interleukin-2 activity in lung cancer. Am Rev Respir Dis 1987; 136:1327-32.
41. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992;13:265-70.
42. Flier JS, Underhill LH. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
43. Gingras MC, Roussel E, Roth JA, Moser RP. Little expression of cytokine mRNA by fresh tumour-infiltrating mononuclear leukocytes from glioma and lung adenocarcinoma. Cytokine 1995; 7:580-8.
44. Mantovani A. Biology of disease. Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines. Lab Invest 1994;71:5-16.
45. Ueki N, Nakazato M, Okhawa T, Ikeda T, Amuro Y, Hada T, et al. Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth. Biochem Biophys Acta 1992;1137:189-96.
46. Takanami I, Imamura T, Hashizuma T, Kikuchi K, Yamamoto Y, Kodaira S. Transforming growth factor β1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol 1994;47:1098-100.
47. Tushinski RJ, Mulé JJ. Biology of cytokines: The interleukins. In: De Vita VT, Jr, Hellman S, Rosenberg SA, editors. Biologic Therapy of Cancer. J.B. Lippincott, Philadelphia: 1995: 87-102.
48. Varmus H, Weinberg RA. Genes and the Biology of Cancer. New York: Scientific American Library, 1993.